Overview

Bupivacaine (brand names include Marcaine®) is a long-acting local anesthetic belonging to the amide class of local anesthetics. It is widely used in regional anesthesia, including peripheral nerve blocks, epidural anesthesia, and field blocks for surgical or obstetric procedures. Its efficacy stems from its ability to block sodium channels, thereby inhibiting nerve impulse transmission.

Pharmacology & Mechanism of Action

Bupivacaine acts primarily by binding to voltage-gated sodium channels on neuronal membranes, preventing the influx of sodium ions during depolarization. This action impedes the initiation and propagation of action potentials, resulting in reversible sensory and motor blockade.

• Onset: 10–20 minutes for infiltration; up to 30 minutes for epidural administration.
• Duration: Up to 8–12 hours for peripheral nerve blocks; 24–72 hours for regional techniques such as epidural or caudal blocks (longer with liposomal formulations).
• Selectivity: Bupivacaine preferentially affects larger, myelinated fibers first (pain and temperature), followed by smaller, unmyelinated C fibers (motor function).

Unique Properties:

• Bupivacaine has a high lipid solubility, contributing to its long duration of action.
• It also exhibits anti-inflammatory effects via binding to prostaglandin E2 receptors (EP1 subtype), reducing fever and inflammation.

Clinical Uses

Bupivacaine is indicated for:

• Peripheral nerve blocks (e.g., brachial plexus, lumbar plexus, sciatic nerve).
• Epidural anesthesia for obstetric labor and postoperative pain management.
• Caudal block for cesarean delivery or lower limb surgery.
• Topical application in minor surgical procedures.

Dosage Guidelines

Dosage must be individualized based on patient factors, site of administration, and desired duration of anesthesia.

Infiltration Anesthesia

• 0.25% solution: Up to 175 mg per injection (typically for infiltration at surgical sites).

Epidural Anesthesia

• 0.5% or 0.75% solutions:
  • Adults: 10–20 mL increments; monitor for toxicity.
  • Obstetrics: 50–100 mg per dose, with strict limits on total daily dose and use of preservative-free formulations.
  • Caudal block: 15–30 mL (0.25% or 0.5%) as needed.

General Considerations

• Administer in small increments to allow detection of intravascular or inadvertent intrathecal injection.
• Avoid rapid bolus administration to minimize risk of systemic toxicity.

Pharmacokinetics & Pharmacodynamics

• Metabolism: Hepatic (via CYP3A4).
• Clearance: Proportional to hepatic function; reduced in liver disease.
• Protein binding: High (~95%).
• Volume of distribution: ~1.5 L/kg.

Onset and Duration:

• Varies by route and concentration; higher concentrations provide longer duration but increased cardiotoxicity risk.

Side Effects & Adverse Events

Systemic Toxicity (Local Anesthetic Systemic Toxicity, LAST)

• Early signs: Circumoral numbness, metallic taste, tinnitus.
• Progression: Central nervous system excitation (anxiety, seizures), followed by cardiovascular depression (hypotension, arrhythmias, cardiac arrest).

Common Local Effects

• Transient injection site pain, bruising, or transient neurologic symptoms.

Other Reported Adverse Events

• Gastrointestinal: Nausea, vomiting.
• Urinary/fecal incontinence (rare).
• Temporary visual disturbances.
• Rarely: cartilage loss with repeated intra-articular injections (especially in pediatric patients).

Drug Interactions

• No severe drug-drug interactions are widely recognized.
• Caution advised with:
  • Other sodium channel blockers (e.g., lidocaine, mepivacaine).
  • Medications that prolong QT interval or affect cardiac conduction.
  • Hepatic enzyme inducers/inhibitors may alter plasma levels.

Contraindications

• Absolute: G6PD deficiency, second-degree AV block, severe hepatic impairment, shock, acute myocardial infarction, known hypersensitivity.
• Relative/Precautions: Pregnancy (use only if benefits outweigh risks), renal failure, heart block, severe hypovolemia.

Special Populations

Pregnancy & Lactation

• Use with caution; limited data but generally considered safe when medically necessary.

Pediatrics

• Lower total doses per kg body weight; monitor closely for toxicity due to immature hepatic metabolism and higher risk of CNS effects.

Precautions & Safety

• Monitor vital signs closely during administration.
• Avoid intravascular injection—use aspiration technique.
• Watch for early signs of toxicity (tinnitus, metallic taste, circumoral numbness).
• Hyperthermia risk: Rare but possible; monitor temperature in prolonged procedures.

Storage

• Store at 20–25°C (68–77°F); excursions up to 15–30°C are acceptable.
• Protect from light and moisture.

Summary for Pharmacists

Bupivacaine is a potent, long-acting local anesthetic with significant clinical utility in regional anesthesia. Its use requires careful dosing, vigilant monitoring for toxicity (especially cardiovascular and CNS), and awareness of patient-specific contraindications. Pharmacists play a critical role in ensuring safe preparation, dispensing, and counseling regarding administration, potential adverse effects, and drug interactions.

References:

• Miller’s Anesthesia, 9th Edition
• Clinical Anesthesia Pharmacology, 6th Edition
• FDA Labeling for Bupivacaine (Marcaine®)
• UpToDate: Local anesthetics: Mechanisms of action, clinical use, and toxicity

Key Points for Practice:

• Always verify patient allergies, comorbidities, and current medications.
• Educate prescribers on safe dosing and monitoring protocols.
• Recognize early signs of systemic toxicity—prompt intervention is lifesaving.